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ARTICLE OPEN
Onchocerca volvulus bivalent subunit vaccine induces
protective immunity in genetically diverse collaborative cross
recombinant inbred intercross mice
Nathan M. Ryan1,10, Jessica A. Hess1,10, Fernando Pardo-Manuel de Villena2, Benjamin E. Leiby3, Ayako Shimada3, Lei Yu4,
Amir Yarmahmoodi4, Nikolai Petrovsky 5, Bin Zhan6,7, Maria Elena Bottazzi 6,7, Benjamin L. Makepeace 8, Sara Lustigman 9 and
David Abraham 1✉
This study tests the hypothesis that an Onchocerca volvulus vaccine, consisting of two recombinant antigens (Ov-103 and Ov-RAL-2)
formulated with the combination-adjuvant Advax-2, can induce protective immunity in genetically diverse Collaborative Cross
recombinant inbred intercross mice (CC-RIX). CC-RIX lines were immunized with the O. volvulus vaccine and challenged with third-
stage larvae. Equal and significant reductions in parasite survival were observed in 7 of 8 CC-RIX lines. Innate protective immunity
was seen in the single CC-RIX line that did not demonstrate protective adaptive immunity. Analysis of a wide array of immune
factors showed that each line of mice have a unique set of immune responses to vaccination and challenge suggesting that the
vaccine is polyfunctional, inducing different equally-protective sets of immune responses based on the genetic background of the
immunized host. Vaccine efficacy in genetically diverse mice suggests that it will also be effective in genetically complex human
populations.
npj Vaccines            (2021) 6:17 ; https://doi.org/10.1038/s41541-020-00276-2
INTRODUCTION
Onchocerciasis, also referred to as river blindness, is a debilitating
eye and skin disease caused by the filarial worm Onchocerca
volvulus and is the world’s second leading cause of infectious
blindness. The primary area of endemicity for O. volvulus is sub-
Saharan Africa, where an estimated 120 million people are at risk
of developing onchocerciasis with 20 million infected and 1.2
million suffering from vision impairment or blindness1. The life
cycle of this parasite begins when an O. volvulus infected black fly
of the genus Simulium takes a blood meal and deposits infective
third-stage larvae (L3) into the human host’s dermal tissues. Once
in the host, the L3 complete two molts to develop into male and
female adult worms that mate and produce microfilariae, which
are responsible for transmission and most of the pathology
associated with the infection. The microfilariae in the skin of an
infected individual are ingested by black flies during a blood meal
and develop into L3 to continue the life cycle2.
Presently, control of onchocerciasis is through the mass drug
administration (MDA) of ivermectin which has a number of
challenges preventing complete disruption of transmission within
endemic areas. (1) Ivermectin is only effective at killing the
microfilariae, requiring annual MDA for 14 years during the
reproductive lifespan of the adult female worms3. (2) Treatment of
patients with ivermectin in several geographic locations resulted
in suboptimal microfilaricidal responses4–6. (3) Severe adverse
reactions may occur if treatment is delivered to individuals that
also have high Loa loa microfilaremia7,8. (4) Non-compliance in
taking ivermectin within some endemic populations prevents
effective control of transmission9. (5) Ivermectin is not recom-
mended for use in children under 5 years of age leaving a large
group of individuals untreated and thus creating a reservoir for O.
volvulus transmission10. Therefore, it is critically important that
MDA with ivermectin be supplemented with additional interven-
tion tools, including macrofilaricides, vector control11 and a
prophylactic vaccine for prevention of infection with O. volvulus 12.
The lack of small animal models for studying O. volvulus led to
the development of a novel system, in which diffusion chambers
containing L3 are implanted subcutaneously into mice. Mem-
branes adhered to the diffusion chamber rings contain the larvae
within, while allowing host cells and soluble immune components
to traffic freely13, thereby providing a unique opportunity to
explore how the murine immune components interact with the
parasite within its microenvironment. Studies using the diffusion
chamber mouse model have demonstrated that immunization
with irradiated L3 induced a protective immune response against
O. volvulus that was dependent on Th2 cytokines, IgE and
eosinophils14. Vaccination of populations living in endemic
regions with attenuated L3 is not technically feasible. To
overcome this obstacle, studies were performed to identify
subunit vaccine antigens that, when combined with an adjuvant,
elicit significant protection against challenge with L315,16. Two
recombinant antigens, Ov-103 and Ov-RAL-2, have been identified
as lead candidates for an O. volvulus vaccine. When formulated
with alum as the adjuvant, these two antigens achieved the
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greatest reduction in larval survival in BALB/cByJ mice, as
compared to other candidate antigens17. This observation was
confirmed using homologous antigens from the filarial worm
Brugia malayi. Induction of protective immunity against the L3
infection was accomplished by vaccinating gerbils with alum-
adjuvanted Bm-103 and Bm-RAL-2 antigens individually or in
combination18.
To increase potency of the O. volvulus vaccine in mice, various
adjuvant formulations were tested. The result was the selection of
Ov-103 and Ov-RAL-2 with the combination-adjuvant Advax-219
(Ov vaccine) as the optimal formulation. The Ov vaccine
consistently induced significant larval killing through a balanced
Th1/Th2 adaptive immune response20. A mixed Th1/Th2 cellular
response against the infective stage of the parasite appeared to be
essential for the protective immunity to O. volvulus that develops in
putatively immune individuals and in infected individuals who
developed concomitant immunity to the infection21,22.
All previous pre-clinical development of the Ov vaccine was
based on experiments done exclusively in BALB/cByJ and C57BL/
6J mice. While these studies have established the vaccine’s
efficacy and its dependence on humoral and cellular immu-
nity20,23, they are limited by the genomic homogeneity within
these two inbred strains of mice24. The lack of genetic diversity in
these animal models may become an issue when the vaccine is
advanced to clinical trial in humans, when more diverse host
genetics may impact vaccine efficacy25–28. Several studies have
described the effects of host genetics on O. volvulus pathogenesis
and disease outcome. Polymorphism in the IL13 gene caused an
increase in serum IL-13 and IgE after exposure to O. volvulus,
resulting in sowda, a hyper-reactive form of onchocerciasis
characterized by increased skin eosinophilia29. Furthermore, study
of human populations in West Africa linked an HLA-D haplotype to
persons that are either immune to reinfection or remain free of
infection despite multiple exposures30. Therefore, it is important to
consider the potential effects that host genetics might have on
the efficacy of the Ov vaccine.
A panel of genetically diverse mice, Collaborative Cross
recombinant inbred strains (CC-RI), was developed using eight
founder strains, of which five were classical inbred strains and
three were wild-derived inbred strains31. CC-RI lines were
generated by three generations of intercross breeding using
varied combinations of founder strains followed by inbreeding to
establish homogeneity within the lines. This resulted in the
creation of recombinant mouse lines with greater genetic diversity
while retaining reproducibility32. To further increase the
magnitude of genetic diversity and to test outbred rather than
inbred individuals, CC Recombinant Inbred Intercross mice (CC-
RIX) were generated through crosses of CC-RI mice resulting in F1
hybrid lines. This design increases diversity when compared to CC-
RI, and creates outbred mice with reproducible genomes within
CC-RIX lines33. The 8 CC-RIX lines chosen for this study were
selected to maximize genetic diversity captured by the lines (on
average 6.8 haplotypes of a maximum of 8 are present genome-
wide), breeding performance, and reproducibility of each line34.
The capacity of the Ov vaccine to induce elimination of
challenge larvae was evaluated in 8 genetically diverse CC-RIX
lines. Comprehensive analysis of multiple immune factors,
measured systemically and locally at the site of the challenge
infection, was performed to determine associations between larval
killing and specific immune responses. Protective immunity
developed in 7 out of the 8 CC-RIX lines, each through a unique
combination of immune responses. The present study demon-
strates that the Ov vaccine can induce protection against O.
volvulus infection through multiple unique mechanisms, based on
the genetic background of the host, which suggests that the Ov
vaccine could be successful in protecting heterogeneous human
populations from this infection.
RESULTS
Protective immunity in genetically diverse CC-RIX lines
BALB/cByJ mice and 8 CC-RIX lines were vaccinated with the Ov
vaccine composed of two antigens, Ov-103 and Ov-RAL-2,
formulated with Advax-2 as the adjuvant. Vaccinated and adjuvant
control mice received challenge infections consisting of L3 within
diffusion chambers implanted subcutaneously. Vaccinated BALB/
cByJ mice and 7 of the 8 CC-RIX mouse lines were protected
against L3 challenge as indicated by statistically significant
reductions in larval survival ranging from 34%–49% as compared
to controls (Fig. 1). Assessing protective immunity based on the
mouse gender indicated that, with the exception of vaccinated
female mice from Line R, both male and female CC-RIX mice
developed vaccine-induced protective immunity at equivalent
levels (Supplementary Table 1). Vaccine-induced protection
against larvae was not observed in Line A, with survival of the
larvae in the adjuvant control group (44%) equivalent to that of
the vaccinated mice (41%) and significantly lower than the mean
parasite recovery from the adjuvant controls for the other 7 CC-RIX
lines (71% ± 14, p < 0.001) (Fig. 1).
Fig. 1 Survival of larval Onchocerca volvulus in control and immunized CC-RIX and BALB/cByJ mice. Mice were vaccinated intramuscularly
with Ov-103 and Ov-RAL-2 formulated with Advax-2 (red triangles) while the control mice received only Advax-2 (blue circles). Diffusion
chambers containing challenge infections of 25 O. volvulus infective third-stage larvae were recovered one-week after implantation and larval
survival was determined. Mean percent larval survival ± standard deviations are marked for each group. n values for each group are listed
above each strain/line, while percent reduction in larval survival comparing vaccinated to controls is listed below each strain/line. *statistically
significant, p ≤ 0.05, when comparing results from control mice to vaccinated mice within each strain/line.
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Local immune responses to challenge parasites measured in
diffusion chambers
Populations of immune cells that migrated to the parasite
microenvironment in the diffusion chambers were identified and
quantified using flow cytometry. In the control mice from BALB/
cByJ and CC-RIX lines exhibiting vaccine-induced protective
immunity, the median total number of cells found within the
diffusion chambers ranged from 2,966 (Interquartile Range (IQR):
1,208–3,658) cells in Line R to 18,032 (IQR: 11,806–26,022) cells in
Line H. Whereas in vaccinated and protected mice, the total
number of cells ranged from 1,691 cells in Line R to 36,903 cells in
BALB/cByJ (Table 1). The only statistically significant increases in
the total number of cells seen in the diffusion chambers recovered
from protected mice, as compared to adjuvant controls, was in
BALB/cByJ mice and Line D mice. The most abundant cells found
within the diffusion chambers for all mice regardless of vaccina-
tion status and strain/line were neutrophils and natural killer (NK)
cells (Table 1).
Several cell types were found to be significantly increased in
vaccinated BALB/cByJ and Line D mice as compared to control
mice, but not in the other CC-RIX lines. In BALB/cByJ, there were
significant increases in the number of B cells, T cells, monocytes,
neutrophils NK cells. In Line D mice, macrophages, neutrophils,
dendritic cells and NK cells were significantly increased (Table 1,
Fig. 2). Despite vaccine-induced larval killing in 7 of 8 CC-RIX lines
and in BALB/cByJ mice, there were no statistically significant
correlations measured between the number of larvae killed in
protected mice and either the total number of cells or the number
of cells from individual cell types within the diffusion chambers.
To identify soluble immune factors that might be associated
with vaccine-induced protection, 11 cytokines and 9 chemokines
within the diffusion chamber fluid were measured. All of the 9
chemokines were detected within the diffusion chambers
recovered from vaccinated and control mice, however only 3
cytokines, G-CSF, GM-CSF and TNF-α, were present in high enough
concentrations to be detected. The only significant increases in
median concentration, detected in protected mice as compared to
controls, were MCP-1, MIG and RANTES in BALB/cByJ, and MIG and
MIP-1α in Line B (Table 2, Fig. 2). None of the levels of cytokines or
chemokines that were detected correlated with the number of
larval killed, nor were there any cytokines or chemokines that
were consistently increased across all protected CC-RIX lines and
in BALB/cByJ.
Line A, which had low parasite recovery-rates in control mice
and the absence of enhanced protective immunity in vaccinated
mice, did not have statistically significant changes in cell count
within the diffusion chambers for any cell type when comparing
vaccinated and control mice. Comparing cytokines and chemo-
kines measured in the diffusion chambers of vaccinated and
control Line A mice revealed statistically significant increases in
only MIP-2 and TNF-α. Due to the low parasite recovery-rate in
control mice of Line A, local immune responses in these mice
were compared to the combined control mice from BALB/cByJ
and the other 7 CC-RIX lines. Diffusion chambers from control
mice from Line A had statistically significant increases in total
cells, dendritic cells, neutrophils, macrophages, T cells and B
cells when compared to the other control mice (Table 3a).
Measurement of chemokines and cytokines from the diffusion
chambers demonstrated statistically lower median concentra-
tions of 6 of 9 chemokines and 1 of 11 cytokines while all others
remained equivalent between control Line A and all other
controls (Table 3b).
Systemic immune responses
Systemic immune responses in protected mice were evaluated by
measuring 14 cytokines in the supernatants of spleen cells
following re-stimulation with the antigens Ov-103 or Ov-RAL-2
ex vivo. Protected BALB/cByJ and Lines B, R and W had increases
in Th1, Th2 and Th17 cytokines in response to either Ov-103 or Ov-
RAL-2. When comparing protected and control mice, Line D had a
Table 1. Cell profiles within fluid recovered from diffusion chambers implanted in BALB/cByJ and 8 CC-RIX Lines.
BALB/cByJ A B D F H M R W
NK Cells 9433* [2×] 7273 3594 3112* [3×] 1398 2442 1888 396 1699
(5411, 28,981) (4579, 13,442) (392, 84,492) (2428, 13,948) (696, 2279) (1841, 4371) (1557, 2066) (206, 819) (1132, 3739)
Dendritic Cells 279 1343 745 636* [4×] 579 535 1023 248 1300
(188, 525) (929, 3759) (104, 23,065) (445, 1726) (335, 1156) (394, 1104) (527, 1082) (183, 409) (880, 2019)
Neutrophils 14042* [3×] 11740 1315 11298* [7×] 2133 6204 305 307 4494
(4134, 43,746) (6297, 31,143) (313, 151,125) (8620, 35,869) (606, 5372) (3440, 11373) (174, 616) (224, 1365) (1995, 7593)
Eosinophils 440 68 14 148 108 433 86 27 14
(181, 970) (41, 136) (13, 54) (27, 256) (54, 136) (102, 1032) (66, 122) (17, 32) (14, 20)
Monocytes 315* [1.4×] 79 122 271 54 165 68 31 67
(150, 2234) (54, 150) (0, 875) (202, 835) (27, 135) (89, 1064) (33, 135) (19, 82) (41, 108)
Macrophages 300 914 1043 1279* [9×] 121 837 623 49 1124
(189, 1050) (604, 4385) (13, 1538) (459, 1845) (67, 691) (526, 1320) (336, 698) (27, 123) (807, 2912)
T Cells 1480* [2×] 951 678 499 496 777 223 479 284
(724, 2424) (590, 1376) (418, 5551) (284, 988) (364, 686) (660, 983) (169, 321) (433, 638) (264, 902)
B Cells 534* [2×] 573 532 406 393 308 95 126 183
(291, 927) (302, 1117) (26, 4183) (325, 2302) (175, 638) (161, 488) (61, 183) (56, 362) (75, 251)
Total Cells 36903* [3×] 21687 9154 15384* [5×] 6705 12746 4409 1691 10418
(17,671, 75,443) (15,619, 52,068) (1266, 483,136) (12,519, 60,147) (2368, 10,286) (7575, 24,950) (3560, 4586) (1533, 3369) (8359, 13,193)
Single cell suspensions were prepared from fluid recovered from diffusion chambers, stained using fluorescent antibodies and analyzed by flow cytometry.
Median cell counts (number of cells per diffusion chamber) and interquartile ranges for total number of cells and for the 8 different cell types recovered from
immunized CC-RIX and BALB/cByJ mice is presented. When a significant difference between control and immunized mice was observed, the fold increase in
immunized mice over control mice is provided [×]. *statistically significant, p ≤ 0.05, when comparing results from control mice to vaccinated mice within each
strain/line.
The bold values indicate the statistically significant values.
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significant increase in one Th1 cytokine after stimulation with Ov-
RAL-2, while Lines F and M did not have any measurable cytokine
responses to either antigen. The cytokines IL-13, IL-17E, IL-21, IL-
23, IL-27 and IL-33 were not detected in any of the stimulated
splenocyte samples collected from control or protected mice. The
absolute quantity of cytokine produced varied for each cytokine,
for each strain/line and for each antigen. Furthermore, the fold-
increase in cytokine levels produced by cells from protected mice
compared to control responses varied greatly, ranging from a less
than 2-fold increase for many cytokines to a 39-fold increase for
IFN-γ with spleen cells from Line W stimulated with Ov-103. The
data show that the Ov vaccine elicits a mixed cytokine response
after infection within the spleen, however, the data from Lines D, F
and M suggest that a strong cytokine response is not required for
protective immunity (Table 4, Fig. 2). None of the levels of
cytokines that were detected in the restimulated spleen cell
supernatants correlated with the number of larvae killed, nor were
there any cytokines that were consistently increased across all
protected CC-RIX lines and in BALB/cByJ.
The role of antigen-specific antibody in the protective immune
response was evaluated by measuring Ov-103- and Ov-RAL-2-
specific IgG1 and combined IgG2a, IgG2b and IgG2c (IgG2a/b/c)
antibody endpoint titers from serum collected 7 days post-
challenge. Immunized and challenged BALB/cByJ mice and all 8
CC-RIX lines developed antibody responses to at least one of the
antigens, with the responses from each strain/line having its own
unique antibody profile. Antibody responses in mice demonstrat-
ing protective immunity following vaccination included: (a) BALB/
cByJ mice and Lines H and W had elevated IgG1 and IgG2a/b/c
responses specific to both antigens. (b) Lines B, M, and R had an
antigen-specific antibody response to both antigens but not with
both subclasses. (c) Line D had an Ov-RAL-2 response consisting of
both IgG1 and IgG2a/b/c but no response to Ov-103. (d) Line F
only had significant increase in Ov-RAL-2-specific IgG2a/b/c. All of
the protected strain/lines, except for Line B, had a significant Ov-
RAL-2-specific IgG2a/b/c response (Table 5, Fig. 2). No statistically
significant correlations were found between antigen-specific
antibody titer and the level of larval killing.
Fig. 2 Heatmap summarizing reduction in parasite recovery, and antibody, cytokine, cell recruitment and chemokine responses. Percent
reduction in larval survival comparing vaccinated to control mice is presented on the top row for each strain/line. The data collected from all
mice from the present study are summarized using Wilcoxon exact tests. p-values were calculated using Monte Carlo estimation and false
discovery rate (FDR)-controlling procedures to compare each measured immunological factor between control and vaccinated mice following
challenge. p-Values that approach 1.00 appear in white boxes and progress to blue and then red boxes as they approach a significant p ≤ 0.05.
Serum – measurement in the serum of Ov-RAL-2 and Ov-103 specific IgG1 and IgG2a/b/c; Spleen Cells – measurement of cytokines in
supernatant after re-stimulation of spleen cells with Ov-RAL-2 and Ov-103. Diffusion Chamber Fluid – total number and specific cell types as
well as measurement of cytokines and chemokines in the parasite microenvironment.
N.M. Ryan et al.
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Mice in Line A, which did not demonstrate vaccine induced
protective immunity, had statistically significant increases in Th1,
Th2 and Th17 responses to Ov-103 and significant increases in Th2
and Th17 responses to Ov-RAL-2 when comparing control and
vaccinated mice (Table 4). Antibody responses in vaccinated Line
A were similar to mice from Line D, both having a statistically
significant increases in Ov-RAL-2-specific IgG1 and IgG2a/b/c
antibody titers (Table 5, Fig. 2). Stimulated spleen cell cytokine
responses from control mice in Line A compared to combined
control mice from the 7 other CC-RIX lines and BALB/cByJ were
significantly increased for IL-6 in response to Ov-103 and for IFN-γ
to Ov-RAL-2, while demonstrating statistically significant decreases
in several other cytokines (Table 3c).
DISCUSSION
A significant reduction in O. volvulus larval survival was observed
in 7 of the 8 CC-RIX lines and in BALB/cByJ mice that were
vaccinated with Ov vaccine, a bivalent vaccine composed of Ov-
103 and Ov-RAL-2 antigens and formulated with Advax-2
adjuvant. These outcomes clearly validate the effectiveness of
the Ov vaccine at inducing protective immunity in a wide range of
genetically-diverse mice. Comprehensive analyses including larval
survival, local immune responses measured in the diffusion
chambers and systemic immune responses measured in the re-
stimulated spleen cells and serum revealed that each strain/line of
mice developed a unique combination of the measured immune
factors. There were no statistically significant correlations between
individual or groups of immune factors and extent of larval killing,
either across all protected mice or within each individual strain/
line, that could serve as an indicator of the mechanism of
protective immunity. The inability to identify correlations may be
explained by the limited variation in parasite recoveries observed
within the vaccinated and protected mouse lines and their
associated highly variable immune responses. There was no single
or group of immune factors that were consistently elevated across
all protected mice, suggesting that each strain/line of mice
developed protection through a unique mechanism.
Previous studies of protective immunity induced by the
antigens Ov-103 and Ov-RAL-2 adjuvanted with Advax-2 utilized
a co-administration protocol in which the antigens were injected
individually into the mice at a single time point. BALB/cByJ mice
immunized with the co-administered antigen vaccine developed
protective immunity that resulted in a 47% reduction in the mean
larval survival20. A similar reduction in larval survival (43%) was
observed in this study where BALB/cByJ mice were vaccinated
with the Ov vaccine injected as one inoculum consisting of both
antigens formulated with Advax-2. Importantly, 7 of the 8
vaccinated CC-RIX lines were also protected with a similar
34%–49% reduction in larval survival. These observations support
the conclusion that the Ov vaccine can induce adaptive protective
immunity regardless of the genetic background of the host.
Furthermore, the vaccine’s efficacy was equal in both male and
female mice, except in Line R. These studies provide evidence that
the Ov vaccine has the potential to be effective in the
Table 2. Cytokine and chemokine profiles in fluid recovered from diffusion chambers implanted in BALB/cByJ and 8 CC-RIX Lines.
BALB/cByJ A B D F H M R W
G-CSF 5537 5382 10012 7856 4832 9714 2371 1820 8016
(3279, 11,773) (4060, 6003) (7300, 11,773) (3292, 11,773) (3900, 6333) (3421, 12,992) (1729, 4277) (1154, 3250) (6228, 12,992)
Eotaxin 822 71 1033 408 651 224 103 62 64
(355, 1407) (36, 231) (457, 1551) (258, 562) (368, 864) (88, 362) (78, 201) (44, 118) (48, 155)
GM-CSF 14 4 20 20 7 12 6 5 21
(9, 23) (0, 8) (8, 30) (17, 23) (6, 14) (7, 39) (4, 12) (2, 7) (12, 27)
IP-10 3192 236 1549 1255 179 649 553 436 849
(2553, 4917) (202, 307) (1123, 1722) (844, 1836) (138, 392) (485, 3151) (428, 892) (252, 552) (428, 991)
KC 1369 4560 4707 8016 4362 3477 3171 1359 8394
(637, 2124) (3503, 5201) (2997, 5424) (3640, 11,584) (1745, 7697) (1544, 8591) (2836, 5039) (989, 2063) (2218, 12,277)
MCP-1 3003* [2×] 1028 5807 4407 929 1062 1300 1487 633
(1491, 9838) (509, 1542) (4441, 8806) (1537, 6476) (729, 1293) (629, 1914) (1056, 3318) (575, 1947) (503, 956)
MIP-1a 1753 1693 1654* [2×] 1656 1095 859 528 599 1886
(1135, 2855) (1496, 3805) (919, 9354) (1051, 4958) (752, 2503) (699, 3426) (328, 734) (373, 1021) (772, 3517)
MIP-1b 3106 1612 1396 2207 968 962 621 595 1510
(1785, 14,514) (1323, 16,586) (786, 11,230) (1471, 3799) (731, 1455) (475, 14,514) (300, 763) (343, 958) (433, 5730)
MIP-2 1273 3518* [3×] 3245 6270 5985 960 1858 776 2650
(796, 2163) (2076, 6070) (1689, 17,551) (3128, 12,015) (1607, 6787) (381, 2349) (1772, 3057) (560, 1005) (1077, 7526)
MIG 474* [2×] 15 237* [4×] 64 6 59 16 26 208
(289, 895) (10, 47) (55, 678) (0, 130) (3, 14) (0, 243) (0, 132) (6, 49) (139, 260)
RANTES 70* [2×] 4 28 15 0 12 5 3 10
(26, 131) (3, 6) (10, 101) (8, 19) (0, 5) (4, 82) (3, 9) (0, 9) (5, 23)
TNF-α 283 602* [3×] 314 626 133 595 215 113 294
(185, 400) (346, 775) (181, 1216) (214, 1038) (84, 275) (229, 1973) (185, 464) (76, 181) (239, 517)
Levels of 11 cytokines and 9 chemokines within diffusion chamber fluid recovered from BALB/cByJ and the 8 CC-RIX lines were analyzed by Luminex. Data
shown (median concentrations [pg/ml] with interquartile ranges) are from immunized mice. Data for the 8 cytokines that were not detected have been
omitted. *statistically significant, p ≤ 0.05, when comparing results from control mice to vaccinated mice within each strain/line. When a significant difference
between control and immunized mice was observed, the fold increase in immunized mice over control mice is provided [×].
The bold values indicate the statistically significant values.
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heterogeneous human populations living in endemic regions for
onchocerciasis.
The Ov-103 and Ov-RAL-2 vaccine antigens induced consistent
levels of protective immunity, resulting in killing of approximately
40% of challenge larvae, regardless of route of administration17,
adjuvant and formulation20, and as shown in this study, host
gender, host genetic background, or the type and magnitude of
the immune response. These observations suggest that the
absence of complete elimination of larvae in the immunized mice
was not due to a deficiency in the immune response, but rather
due to changes in susceptibility of the larvae as they develop from
L3 to fourth-stage larvae (L4). L3 begin to molt into L4 starting on
day 3 post-infection13 and the surface of the synthesized L4
cuticle was shown to have its own unique characteristics in O.
volvulus and other filarial worms35,36. In the present study, the
diffusion chambers were implanted for one week, whereas in
previous studies using the co-administered antigens, they were
implanted for three weeks17,20. Despite allowing more time for the
immune response to kill the worms, the same level of parasite
killing was observed. Thus, it appears that some worms within
diffusion chambers are able to evade the immune killing process
during the three weeks in mice. It is possible, that if worm
development was allowed to continue, their changing surfaces
might have resulted in a renewed susceptibility to immune-
mediated killing. Alternatively, developing parasites may boost the
vaccine-induced immune response resulting in continued parasite
killing. Support for this hypothesis can be found in the report
where dogs, immunized against Dirofilaria immitis with
chemically-abbreviated infections, killed 63% of larvae at 3-
weeks post-challenge when contained within diffusion chambers,
but 98% of the challenge parasites were killed at 7 months when
the adult parasites were recovered from the infected tissues37.
Further support for this hypothesis can also be found in the
studies in which gerbils were vaccinated with B. malayi homo-
logous antigens Bm-103 and Bm-RAL-2 and numbers of adult
worms recovered after 90 days post challenge were reduced by
approximately 60%18. Thus, the Ov vaccine could be significantly
more effective when the immune response has a longer time to
kill the various parasite stages during their development in the
host and/or when the worms are within their niche, subcutaneous
tissues, as compared to when they are contained within diffusion
chambers for a limited time period. Modeling studies concluded
that an initial vaccine prophylactic efficacy of 50% and an initial
therapeutic efficacy of 90% would markedly reduce microfilarial
load in the young age groups protecting them from the morbidity
and mortality associated with onchocerciasis. Most benefit would
be gained from a long-lived vaccine even if only partially
protective38. However, it must be emphasized, that a 40%
reduction in larval survival would still have a meaningful clinical
benefit, translating into a significant reduction in the number of
viable adults that colonize the host tissues and thus reducing the
number of microfilariae they produce. Microfilarial loads have
been directly linked to the pathology caused by O. volvulus39,40
and a reduction in microfilariae in the skin would also limit
transmission of the disease.
It is clear that each CC-RIX line developed a unique immune
response following immunization with the Ov vaccine and
challenge, and that in 7 out of 8 CC-RIX lines and BALB/cByJ mice
this multifactorial adaptive immunity resulted in a significant
killing of the challenge larvae. The one exception was Line A
where parasite recovery in the control and vaccinated mice was
equal despite strong Th1, Th2 and Th17 cytokine responses in the
stimulated spleen cells and IgG2a/b/c response to Ov-RAL-2 in the
vaccinated and challenged mice. Parasite recoveries from control
mice from Line A were at equivalent levels to that seen in the
protected mice from the other CC-RIX lines and BALB/cByJ,
suggesting that Line A control mice had an inherent reduction in
susceptibility to infection with O. volvulus larvae. This hypothesis is
supported by the observation of highly elevated numbers of
dendritic cells, macrophages, neutrophils, T cells, B cells and total
cells found in the diffusion chambers recovered from Line A
control mice after challenge as compared to control mice from the
other strains/lines. While the cell numbers increased in Line A
control mice, there was a concurrent decrease in chemokine levels
Table 3. Comparison between immune factors measured in Line A control mice compared to levels measured in CC-RIX and BALB/cByJ control mice.
(a) Diffusion chamber cell count (b) Diffusion chamber cytokines and
chemokines
(c) Spleen cell supernatant cytokines
Variable NOT A (n= 114) A (n= 9) Variable NOT A (n= 114) A (n= 9) Variable NOT A (n= 114) A (n= 9)
Dendritic Cells 346 1211*↑ Eotaxin 471 186*↓ Ov-103 IL-2 31 14*↓
(122, 650) (804, 1665) (184, 872) (102, 282) (14, 59) (12, 15)
Neutrophils 2377 24209*↑ GM-CSF 12 6*↓ IL-4 66 29*↓
(836, 7723) (13,302, 33,595) (6, 19) (4, 9) (22, 282) (10, 45)
Macrophages 230 2115*↑ IL-9 169 99*↓ IL-5 8 0*↓
(66, 840) (873, 3562) (103, 223) (81, 118) (0, 29) (0, 0)
T Cells 490 1051*↑ IL-10 40 12*↓ IL-6 160 695*↑
(338, 847) (694, 1187) (15, 78) (5, 13) (61, 338) (423, 971)
B Cells 242 830*↑ IP-10 1137 313*↓ Ov-RAL-2 INF-γ 680 4920*↑
(95, 528) (464, 1174) (455, 2968) (227, 477) (160, 1954) (2299, 7327)
Total Cells 7186 36068*↑ MIG 119 15*↓ IL-2 44 19*↓
(3758, 16,451) (21,570, 50,045) (9, 255) (12, 19) (19, 85) (14, 30)
RANTES 9 4*↓ IL-5 24 2*↓
(4, 31) (3, 4) (0, 61) (0, 6)
Median cell counts (number of cells per diffusion chamber (a)), levels of cytokines and chemokines (pg/ml) in the diffusion chamber fluids (b), and cytokine
levels in ex vivo restimulated splenocytes (c) with corresponding interquartile ranges in control mice from Line A and control mice from the other CC-RIX and
BALB/cByJ are presented. The data presented are only for factors with statistically significant differences. (*↑) = statistically significant increase in Line A
compared to combined control mice from all other groups (NOT A); p ≤ 0.05. (*↓) = statistically significant decrease in Line A compared to NOTA control mice;
p ≤ 0.05.
The bold values indicate the statistically significant values.
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within the diffusion chamber fluid. This observation might be
explained by an increase in the rate at which chemokines from
Line A diffused out from the diffusion chamber, resulting in an
accelerated rate of cell chemotaxis up the chemokine gradient
leading to the worms within the diffusion chamber.
Analysis of the cell populations migrating into the diffusion
chambers showed a large degree of variability between the strain/
lines and individual mice. These findings limited the possibility of
identifying statistically significant changes in cell recruitment into
the parasite microenvironment that correlated with parasite
survival, across either all of the protected mice or within each
individual strain/line, after 7 days in vivo. Previous studies
analyzing cell populations in several CC-RIX lines have reported
wide variation in the number of T cell, B cell and antigen
presenting cells41,42, supporting the observations of the present
study. Neutrophils and eosinophils have been implicated in the
mechanism of protective immunity to O. volvulus20, which is
consistent with neutrophil and eosinophil content in the diffusion
Table 4. Cytokine profiles in supernatants from ex vivo antigen-stimulated spleen cells recovered from BALB/cByJ and 8 CC-RIX Lines.
BALB/cByJ A B D F H M R W
Ov-103
Th1
INF-γ 1753* [6×] 5021* [4×] 5381* [2×] 2723 1454 3246* [10×] 645 2321* [17×] 1664* [39×]
(893, 2915) (4599, 7327) (3655, 39022) (450, 18341) (1026, 2969) (677, 4271) (226, 877) (972, 4264) (535, 2792)
IL-2 73* [1.4×] 22 31 53 13 21 30 25 39* [5×]
(50, 110) (18, 31) (17, 33) (43, 147) (8, 28) (14, 27) (18, 37) (19, 31) (26, 41)
Th2
IL-4 168* [3×] 789* [27×] 1446* [3×] 1443 270 41 106 375* [5×] 175* [8×]
(107, 284) (625, 921) (1068, 3124) (772, 1581) (197, 360) (12, 511) (53, 171) (204, 808) (175, 125)
IL-5 90* [9×] 39* [39×] 104* [5×] 7 6 6 13 52* [6×] 8
(38, 159) (13, 144) (73, 115) (0, 66) (0, 13) (0, 15) (10, 34) (32, 76) (6, 10)
IL-6 326* [2×] 2405 686 371 520 108 114 285 548* [8×]
(173, 531) (1636, 2951) (502, 1782) (170, 860) (403, 782) (17, 474) (89, 272) (206, 507) (219, 845)
IL-10 31* [31×] 133* [7×] 55 138 255 54* [3×] 26 69 21* [21×]
(14, 44) (98, 210) (30, 138) (32, 179) (184, 326) (36, 155) (19, 39) (35, 180) (21, 28)
Th17
IL-17F 84* [84×] 51* [51×] 68* [68×] 0 19 0 0 0 0
(32, 209) (28, 72) (54, 248) (0, 0) (0, 53) (0, 0) (0, 0) (0, 24) (0, 0)
Ov-RAL-2
Th1
INF-γ 2322* [3×] 4636 3678* [2×] 5955* [2×] 3200 630 619 3383* [60×] 3711* [17×]
(1100, 4062) (4046, 5806) (2848, 4497) (3607, 39022) (2735, 4571) (0, 7393) (308, 1013) (2042, 6933) (1227, 4366)
IL-2 87 57 32 38 40 16 39 26 42* [5×]
(59, 131) (20, 94) (27, 52) (10, 68) (21, 46) (13, 54) (32, 40) (0, 31) (34, 52)
Th2
IL-4 281* [2×] 631* [5×] 840* [2×] 1239 426 65 205 561* [6×] 552* [13×]
(80, 448) (559, 729) (712, 1050) (926, 1405) (251, 568) (24, 247) (88, 568) (293, 862) (400, 1325)
IL-5 72 33* [17×] 33 26 17 16 20 31 35* [35×]
(18, 153) (19, 74) (24, 134) (9, 49) (10, 28) (12, 22) (11, 105) (23, 37) (21, 82)
IL-6 483 1572* [2×] 842* [2×] 797 1068 1347 347 663* [7×] 4158* [30×]
(223, 1063) (1425, 1932) (468, 1659) (557, 1796) (915, 1361) (115, 2024) (104, 833) (377, 1195) (3260, 5516)
IL-10 54* [2×] 140* [3×] 51 218 374 101 49 63 99* [99×]
(28, 125) (109, 204) (22, 96) (101, 428) (282, 452) (55, 159) (18, 165) (42, 82) (55, 114)
Th17
IL-17A 123* [123×] 34 234* [2×] 0 95 0 0 0 0
(0, 294) (0, 68) (163, 554) (0, 15) (0, 191) (0, 0) (0, 0) (0, 73) (0, 140)
IL-17F 43* [3×] 28* [28×] 89* [2×] 0 109 0 0 0 16* [16×]
(14, 142) (14, 44) (77, 150) (0, 3) (25, 146) (0, 0) (0, 0) (0, 0) (0, 107)
Levels of 14 cytokines in culture supernatants from spleen cells stimulated ex vivo with Ov-103 or Ov-RAL-2 were analyzed by Luminex. Data shown (median
concentrations [pg/ml] with interquartile ranges) are from immunized mice. Data for the 6 cytokines that were not detected have been omitted. (*) =
statistically significant, p ≤ 0.05, when comparing results from control mice to vaccinated mice within each strain/line. When a significant difference between
control and immunized mice was observed, the fold increase in immunized mice over control mice is provided [×]. A non-detectable result was replaced by ‘1’
in the analysis so that the fold difference could be calculated.
The bold values indicate the statistically significant values.
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chambers measured in both control and immunized mice in the
present study. Furthermore, human monospecific anti-Ov-103
antibodies but not anti-Ov-RAL-2 significantly inhibited the
molting of L3 in vitro in collaboration with human neutrophils,
while both anti-Ov-103 and anti-Ov-RAL-2 antibodies significantly
inhibited the molting of L3 in the presence of human
monocytes23. In previous studies, in which diffusion chambers
were implanted for three weeks, significant increases in chemo-
kines within diffusion chambers of the protected mice were
recorded17,20. However, similar findings were not observed in the
present study where the diffusion chambers were implanted for
only one week. Diffusion chambers represent a dynamic environ-
ment in which cells are presumed to be actively migrating into the
diffusion chamber while soluble factors diffuse into and out of the
parasite microenvironment. Flow cytometry of diffusion chamber
contents only provides a single snapshot of the host response that
may reflect the environment either during or after the killing
process, with each phase having its own unique composition of
infiltrating cells and factors.
Cytokine analysis of supernatants recovered from ex vivo
stimulated spleen cells showed that the profile of cytokine
secretion varied based on mouse genetic background with some
lines having a multiple cytokine response to vaccination and
challenge and other lines having no significant cytokine response.
Immunized and protected mice from BALB/cByJ and Lines B, R and
W had increases in Th1, Th2 and Th17 cytokines in response to
both antigens whereas Lines D, F, H and M had minimal or no
measurable cytokine responses to either antigen. Moreover, the
absolute quantity of each cytokine produced by the stimulated
spleen cells varied for each strain/line and for each vaccine
antigen. Previous studies using BALB/cByJ mice, vaccinated with
co-administered Ov-103 and Ov-RAL-2 each formulated with
Advax-2, resulted in the induction of a balanced Th1/Th2-type
immunity similar to the outcomes in the present study, when the
Ov vaccine was administered as one inoculum20. Notably,
putatively immune individuals and infected individuals who
developed concomitant immunity to O. volvulus with age also
displayed a mixed Th1/Th2 response in response to L3 and
molting L3 extracts21,22. Balanced Th1/Th2 immunity has also been
shown to be associated with the development of protective
immunity to Wuchereria bancrofti and B. malayi vaccine anti-
gens43,44. It is clear the Ov-103 and Ov-RAL-2 antigens in the Ov
vaccine can induce Th1, Th2 and Th17 cytokine responses based
on the cytokine profiles of ex vivo re-stimulated spleen cells
recovered from the protected mice. However, the lack of a robust
cytokine response in several of the CC-RIX lines while simulta-
neously having a strong protective immune response, suggests
that strong cytokine responses may not be required for protective
immunity to larval O. volvulus.
Protective immunity induced in C57BL/6J mice by vaccination
with either Ov-103 or Ov-RAL-2 with Advax-2, has been shown to
be IgG-dependent23. In the present study, antigen-specific anti-
body responses in the protected BALB/cByJ and CC-RIX mice
demonstrated that the vaccine induced both IgG1 and/or IgG2a/
b/c responses to either one or both of the vaccine antigens.
Analysis of IgE was not included in the antibody analyses, as
previous studies in which BALB/cByJ mice were immunized with
Ov-103 or Ov-RAL-2 with Advax-2 did not observe antigen specific
IgE responses20. The varied responses across the 7 protected CC-
RIX lines suggest that the antigen-specific antibody responses
following immunization might be controlled by host genetic
background. These findings are consistent with other studies that
have demonstrated genetic control of antibody responses in
mice45,46 and in humans47,48. A mixed IgG1 and IgG2a/b/c
response to both vaccine antigens was observed in protected
BALB/cByJ, consistent with previous studies with the co-
administered vaccine20, and was also observed in Lines H and
W. However, a similar level of protective immunity was observed
in Lines that only responded to Ov-RAL-2, where Line F only
developed antigen-specific IgG2a/b/c and where Line D only
developed IgG1 and IgG2a/b/c to the antigen. It can be concluded
from these antibody response assays that although the Ov vaccine
is composed of two antigens not all CC-RIX lines responded
similarly to vaccination by both antigens. Furthermore, there was a
large range in the antibody endpoint titers in the protected CC-RIX
mice, with no apparent correlation between antibody titer and
efficacy of the killing response within the diffusion chamber. Thus,
a varied antibody response, in terms of IgG subclass, antigen
specificity and endpoint titer, is also associated with equal levels
of protective immunity. This diversity of functional antibody
responses portents well for the efficacy of the Ov vaccine as it is
translated into clinical use.
The vaccine formulation used in this study was selected to
maximize the potential of the vaccine to be effective in a wide
Table 5. Antigen-specific antibody endpoint titers measured in BALB/cByJ and 8 CC-RIX Lines serum following vaccination and challenge.




4815* 1668* 899 250,360* 1271* 24,666* 2421* 1061* 223,142*




(221, 2917) (290, 2050) (100,586,
564,381)
IgG1 55443* 1527* 688* 98782* 31 89325* 170 28 504425*
(12,809,
173,732)
(303, 9022) (113, 9200) (5072, 402,417) (14, 562) (2308,
370,907)





125* 0 4061* 16 13 933* 559* 5107* 110*
(3, 1305) (0, 13) (569, 879,079) (5, 58) (0, 367) (281, 8152) (208, 2330) (611, 28,230) (9, 45,977)
IgG1 1978* 0 41* 0 0 81* 1245* 4197* 4878*
(131, 148,00) (0, 24) (5, 159,808) (0, 82) (0, 14) (15, 1327) (733, 4205) (1136, 17,846) (40, 48,228)
Antigen-specific (Ov-103 or Ov-RAL-2) and IgG subtype (IgG1 or a combination of IgG2a, IgG2b and IgG2c [IgG2a/b/c/]) endpoint titers were determined using
ELISA on serum collected from vaccinated BALB/cByJ and CC-RIX following recovery of challenge larvae. Median endpoint titers with interquartile ranges are
presented. *statistically significant, p ≤ 0.05, when comparing results from control mice to vaccinated mice within each strain/line.
The bold values indicate the statistically significant values.
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range of host genetic backgrounds. The Ov vaccine is composed
of two vaccine antigens that can independently induce protective
immunity, and when combined act synergistically to induce a
higher level of protective immunity20. Combination adjuvants
have been shown to enhance vaccine efficacy19,49 and the
combination adjuvant Advax-2 which contains a polysaccharide
particle (delta inulin)18 together with a TLR9 agonist (CpG
oligonucleotide) was selected as it was shown to induce a mixed
Th1 and Th2 response when used together with Ov-103 and Ov-
RAL-220. It was hypothesized that vaccinating mice with two
unique antigens, that could function independently, and with an
adjuvant that induces a combined Th1 and Th2 response, would
enhance the probability that the vaccine would function
effectively within a spectrum of genetic backgrounds. Results
from the present study confirmed this hypothesis based on the
observation that protective immunity developed in 7 out of 8 CC-
RIX lines, despite some lines only responding to one of the two
antigens in the Ov vaccine. Furthermore, most of the lines
developed combined Th1, Th2 and Th17 immune responses
although there were lines with dominant Th1 response and others
with uniformly weak cytokine responses. Importantly, this wide
range of cytokine responses to the Ov vaccine all resulted in
equivalent levels of protective immunity to the infection.
It is clear from Fig. 2 that there was an extensive range of
immune responses to the Ov vaccine in the protected BALB/cByJ
and CC-RIX lines, ranging from multi-component to single-analyte
responses, all resulting in the same level of protective immunity.
The remarkable variability in the innate and adaptive immune
responses between the genetically diverse mouse strain and lines
suggests that the Ov vaccine is immunologically polyfunctional in
nature and capable of inducing multiple protective mechanisms.
Alternatively, Ov vaccine-induced protective immunity may
function in CC-RIX mice through a single conserved mechanism
that was not identified in this study. Genetics have been shown to
play a critical role in the rate of success for a variety of vaccines
including those for measles27, influenza25 and hepatitis B26,28 and
are widely believed to be responsible for the variable responses in
other vaccines50. The multi-facetted responses and broad protec-
tion across genetically diverse mouse populations observed in this
study may mirror observations of the yellow fever vaccine, YF-17D,
in humans. A single dose of YF-17D can induce an immune
response consisting of cytotoxic T lymphocytes, balanced Th1/
Th2-type immunity and neutralizing antibodies that can last up to
30 years. This polyfunctional response consisting of multiple
mechanisms of immunity was responsible for the ability of this
vaccine to induce strong protective immunity throughout diverse
human populations51, despite the high degree of variation
observed in antigen specific CD8+ T cell responses and neutraliz-
ing antibody titers52. The findings with YF-17D support the
hypothesis that the polyfunctional Ov vaccine would be optimal
for use in humans.
This study demonstrated that the Ov vaccine is capable of
inducing protective immunity in genetically-diverse mouse lines.
Comprehensive analysis of effector cell recruitment, cytokine and
chemokine concentrations within the parasite microenvironment,
antigen-specific cytokine and antigen-specific serum antibody
responses have supported the conclusion that there is a genetic
basis for the type of innate and adaptive protective immune
responses induced by the Ov vaccine. It was hypothesized that the
vaccine could potentially induce multiple killing mechanisms, and
in this study, we show that each CC-RIX line uses its own unique
combination of immune factors to eliminate the parasites. Future
studies are required to further define specific biomarkers of
vaccine efficacy and to dissect the mechanisms of the protective
immune response. The results from this study show that the Ov
vaccine functions in a wide range of host genetic backgrounds
and suggest that the vaccine will translate effectively into clinical
use, protecting diverse human populations from infection with O.
volvulus through a variety of effective protective mechanisms.
MATERIALS AND METHODS
Source of parasites
O. volvulus L3 were isolated from newly emerged adult black flies
(Simulium damnosum) that fed on consenting infected donors (Protocol
320, approved by the New York Blood Center and the Medical Research
Station, Kumba, Cameroon IRBs). Flies were kept in a controlled insectary,
dissected after one week and the developed L3 were collected, cleaned
and cryopreserved as previously described53.
Source of mice
Male BALB/cByJ mice were obtained from The Jackson Laboratory (Bar
Harbor, Maine). Male and female CC-RIX mice were bred at the System
Genetics Core Facility at University of North Carolina (UNC), Chapel Hill54.
Sixteen different CC-RI lines were selected as parental lines and then
assigned to 8 unique breeding pairs, with each pair comprised of two CC-RI
lines. The following 8 CC-RIX lines were generated with the dam listed first
and the sire listed second, each given a random code letter to ease
analyses: Line A – CC004/TauUnc x CC071/TauUnc; Line B – CC005/TauUnc
x CC001/Unc; Line D- CC019/TauUnc x CC055/TauUnc; Line F – CC039/Unc
x CC003/Unc; Line H – CC051/TauUnc x CC049/TauUnc; Line M – CC042/
GeniUnc x CC007/Unc; Line R – CC040/TauUnc x CC002/Unc and Line W –
CC026/GeniUnc x CC006/TauUnc. All CC-RIX mice were born between 12/
31/2018 and 2/25/2019. Mice were shipped to Thomas Jefferson University
Laboratory Animal Sciences Facility at approximately 5–6 weeks and given
time to acclimate to the facilities before use in experiments. CC-RIX mouse
lines, delivered in multiple shipments due to individual breeding
schedules, were divided into 5 experiments. BALB/cByJ mice were added
to each experiment as the reference strain. All mice were housed in micro-
isolator boxes in specific pathogen free rooms under temperature,
humidity and light cycle-controlled conditions. Mice received water ad
libitum and fed rodent chow sterilized by autoclaving.
Animal ethics
Protocols and procedures were conducted in compliance with ethical and
regulatory standards for animal experimentation set by the National
Institute of Health (NIH). The animal use protocol (00136) was approved by
the Thomas Jefferson University Institutional Animal Care and Use
Committee (IACUC). CC-RI and CC-RIX mice were produced by the Systems
Genetics Core Facility at the University of North Carolina (UNC) (Animal
Welfare Assurance #A3410-01). The animal use protocols for CC-RI mice
(18–288) and for CC-RIX mice (17–285) were approved by the UNC IACUC.
All animal use protocols adhere to the “Guide for the Care and Use of
Laboratory Animals” published by the National Research Council, USA.
Production of antigens
HIS-tagged recombinant Ov-103 was expressed as soluble protein in
PichiaPink yeast and Ov-RAL-2 was expressed in E. coli BL21. Both vaccine
antigens were expressed and purified as previously described17. Endotoxin
was removed with a Q anion exchange column with less than 2.7 EU/mg in
the final products.
Immunization and challenge protocol
Immunization doses for each mouse consisted of 25 µg of each
recombinant antigen, Ov-103 and Ov-RAL-2, mixed with Advax-2 (1 mg
delta inulin plus 10 μg CpG55.2) (Vaxine Pty Ltd, Adelaide, South Australia)
brought to a total volume of 100 µl using Tris-buffered saline (TBS)
(Corning, Corning NY). Adjuvant control consisted of 1 mg Advax-2
brought to a total volume of 100 µl using TBS. On day 0, mice were
immunized intramuscularly with Advax-2-formulated Ov-103/Ov-RAL-2
vaccine, or adjuvant control, by bilateral injection of 50 µl into each
caudal thigh. All mice were boosted twice with either adjuvant control or
adjuvant with the two antigens, at two-week intervals. Two weeks after the
final immunization, all mice were challenged with 25 L3 in a diffusion
chamber surgically implanted in a subcutaneous pocket on the rear flank
of each mouse. The diffusion chambers were constructed with 14mm
Lucite rings covered with 5.0 µM pore-size Durapore membranes
(EMDMillipore, Billerca, MA) and fused together using an adhesive made
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of a 1:1 mixture of 1,2-dichloroethane (Fisher Scientific, Pittsburg, PA) and
acryloid resin (Rohm and Haas, Philadelphia, PA). After assembly, diffusion
chambers were sterilized using 100% ethylene oxide followed by 12 hours
of aeration. The L3 were suspended in a 1:1 mixture of NCTC-135 and
Iscove’s modified Dulbecco’s medium (Sigma, St. Lois, MO) with 100 U
penicillin, 100 µg streptomycin (Corning), 100 µg gentamicin (EMDMilli-
pore) and 30 µg of chloramphenicol (APP Pharmaceuticals LLC, Schaum-
burge, IL) per ml. These antibiotics were selected to control bacterial
contaminants while having no effect on the endosymbiont Wolbachia or
on parasite development55–60. The chambers were recovered 7 days post-
challenge and the contents collected for analysis.
Recovery of larvae from diffusion chambers
The contents of each diffusion chamber were observed under a
microscope and the number of surviving larvae was determined. Percent
reduction of the challenge larvae was calculated by: [(average worm
survival in control mice – average worm survival in immunized mice) ÷
average worm survival in control mice] × 100.
Cell preparation and flow cytometry analysis
Cells were collected from diffusion chambers recovered from the control
and immunized mice. Erythrocytes were lysed using BD Pharm Lyse (BD
Biosciences, San Jose, CA) and recovered cells were filtered using a 70-μm
cell strainer and then washed using FACS buffer [DPBS (Corning), 3% BSA
(Gemini Bio-Products), 5 mM ethylenediaminetetraacetic acid (Sigma-
Aldrich)]. Cells were then stained at 4 °C in the dark for 30minutes with
a 100 μl total volume cocktail of the following antibodies: anti-B220
BUV396 (1:200), anti-CD3e BV711 (1:200), anti-CD8a PerCP5.5 (1:200),
CD11c PE-Cy7 (1:400), anti-Ly6G PE (1:400), anti-CD19 BV786 (1:800), anti-
F4/80 BV421 (1:800), anti-Ly6C AF700 (1:800), anti-NK1.1 FITC (1:800), anti-
CD4 V650 (1:1600), anti-CD11b PE-TxRed (1:1600) (BD Biosciences). The
stained cells were washed and resuspended in 200 μl FACS buffer with
50 μl of CountBright absolute counting beads (Invitrogen, Waltham, MA) to
determine exact cell numbers within the diffusion chambers. Analysis of
cell profiles was conducted on a BD LSRFortessa (BD Biosciences) and the
data was analyzed using FlowJo v10 (FlowJo LLC, Ashland, OR). Cell
populations were determined using a gating strategy that eliminates dead
cells, debris and doublets to identify T cells (CD3+), B cells (CD19+)61, NK
cells (CD3−, CD19−, NK 1.1+)62, dendritic cells (CD3−, CD19−, NK1.1−,
CD11c+, CD11b+), neutrophils (CD3−, CD19−, NK1.1−, Ly6G+, CD11b+,
CD11c−), eosinophils (CD3−, CD19−, NK1.1−, CD11c−, Ly6G−, CD11b+,
Ly6C+, SSCHi), monocytes (CD3−, CD19−, NK1.1−, CD11c−, Ly6G−, CD11b+,
SSClo, Ly6Clo, F4/80lo) and macrophages (CD3−, CD19−, NK1.1−, CD11c−,
Ly6G−, CD11b+, SSClo, Ly6Clo, F4/80hi)63 (Supplementary Fig. 1).
Cytokine and chemokine analysis of fluid recovered from
diffusion chambers
Fluid recovered from the diffusion chambers from each mouse was
analyzed using Milliplex map Kit magnetic bead panels per manufacturer’s
protocols (EMDMillipore) and a MAG-PIX Luminex multiplexing instrument
(Luminex, Austin, TX). Diffusion chamber fluid was analyzed for 11
cytokines (IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, GM-CSF
and G-CSF) and 9 chemokines (eotaxin, RANTES, KC, MCP-1, IP-10, MIG/
CXCL9, MIP-1α, MIP-1β and MIP-2). Analyte concentrations were calculated
using Milliplex Analyst software (EMDMillipore).
Cytokine analysis of antigen-stimulated spleen cell
supernatants
Spleens were collected aseptically at the termination of the experiment,
kept on ice in 0.1% BSA and homogenized into a single cell suspension.
Following lysis of erythrocytes using sterile distilled cold water, the
suspension was filtered through a 70 μm cell strainer and washed using
Dulbecco’s Modified Eagle medium (Corning). Cells were cultured in flat-
bottom 96-well plates, with each well containing 2×106 cells. The cells
were stimulated with 10 μg of either Ov-103 or Ov-RAL-2 for 72 hours at
37 °C. IL-4 uptake by splenocytes was blocked by addition of 0.5 μl of anti-
IL-4R (BD Biosciences) to each well. Supernatants were collected following
incubation and frozen at −20 °C. Cytokines in the supernatants were
analyzed using Milliplex map Kit magnetic bead panels per manufacturer’s
protocols (EMDMillipore) and a MAG-PIX Luminex multiplexing instrument
(Luminex, Austin, TX). Stimulated spleen cell supernatants were analyzed
for 14 different cytokines: IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-21, IL-23,
IL-27, IL-33, IL-17A, IL-17E and IL-17F. Analyte concentrations were
calculated using Milliplex Analyst software (EMDMillipore).
Antigen-specific antibody analysis of serum
Serum collected from each mouse at the termination of the experiment
was tested by enzyme-linked immunosorbent assay (ELISA) for antigen-
specific IgG1, and combined IgG2a, IgG2b and IgG2c (IgG2a/b/c)
responses. Nunc MaxiSorp 96-well ELISA plates (Thermo Fisher) were
pre-coated with 1 μg/ml coating protein (Ov-103 or Ov-RAL-2) in 0.1 M
Carbonate buffer pH 9.6 and left overnight at 4 °C. All wash steps used 1x
TBS+ 0.05% Tween 20 (TBS-T). Wells were blocked using blocking buffer
(2% BSA in 1x TBS-T) for 1 hour at approximately 21 °C and serum samples
serially diluted in blocking buffer, using an appropriate starting dilution for
each antigen and antibody subclass, and incubated for 90minutes at 37 °C.
Following incubation, secondary horseradish peroxidase-conjugated anti-
bodies, goat anti-mouse IgG1 (1:15,000) or anti-IgG2a, IgG2b and IgG2c
(1:15,000 each) (Southern Biotech, Birmingham, AL) were added for
45minutes at approximately 21 °C. The reaction was developed by adding
100 μl of TMB solution (SeraCare, Gaithersburg, MD) for 10minutes for the
IgG1 assays or 15minutes for the IgG2a/b/c assays. The reactions were
stopped by adding 100 μl of TMB stop solution (SeraCare), and the optical
densities (OD) were measured at 450 nm using an iMark plate reader
(BioRad, Hercules, CA). Endpoint titers were calculated using SoftMax Pro
software (Molecular Devices, San Jose, CA) with minimum positive titers
determined by the lowest serum dilution from vaccinated mice with OD
values three times higher than background.
Statistics
Data for parasite survival was analyzed by multifactorial analysis of
variance ANOVA with post-hoc Fisher’s least significant difference testing
in Systat v.11 (Systat Inc., Evanstown, IL). The correlations between
individual immune factors and the percentage recovery of larvae were
analyzed with the Pearson correlation coefficient by strain/line. Each factor
was log-transformed after the value of one added to the original value
before calculating the correlation coefficients. P-values for the correlation
coefficients were adjusted for multiple testing to control the false
discovery rate (FDR)64. Cell counts, chemokine and cytokine content in
the diffusion chambers, levels of cytokines in antigen-stimulated spleen
cell supernatants, and the antigen-specific antibody responses were rank-
transformed prior to analysis. Each immunological factor was analyzed
separately using a mixed effects model that simultaneously evaluated the
effect of vaccination within each line of CC-RIX mice. Fixed effects included
terms for vaccination within each strain/line while the main effect of strain/
line was treated as a random effect. Correlation among the strain/lines was
modeled using a Toeplitz covariance structure for the random effect. P-
values for the vaccine-induced effects within each strain/line were
calculated for each immunological factor and subsequently adjusted for
multiple testing to control the false discovery rate as described64. A heat
map was created as a visual summary of the FDR-adjusted p-values of the
vaccine-induced immunological factors induced within all strain/lines for
all the factors. All analyses were completed using SAS 9.4 and SAS/STAT
15.1 (SAS Institute, Cary, NC).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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